Apogee signs $1.3 billion royalty financing agreement with Blackstone, accelerating Phase 3 entry
Key Points
Apogee Therapeutics has entered into a royalty‑financing agreement with Blackstone Life Sciences for up to $1.3 billion. Its IL‑13‑targeting antibody candidate is poised to enter Phase 3 trials. Because the financing is royalty‑based, upfront cash is limited, with payments tied to a percentage of future sales. Securing this capital is expected to accelerate the move into Phase 3 and improve the likelihood of market entry.
From an investor perspective, a royalty‑financing structure of up to $1.3 billion limits exposure while offering substantial upside if Phase 3 succeeds. For job seekers and industry professionals, the accelerated Phase 3 entry provides valuable drug‑development experience and opportunities to engage with a high‑growth company.
Source: FierceBiotech (rss)